Bitter Compounds – The Forgotten Plant Substances and What Current Research Knows About Them

Gentian, wormwood, dandelion, artichoke and yarrow have been part of Central European plant tradition for centuries – not by chance, but because their effect on digestion, liver function and bile flow was observed empirically across generations. What traditional herbal knowledge has long assumed, modern research is only now beginning to unravel in its full complexity: bitter plant compounds activate not only taste receptors on the tongue, but a recognition system that extends through the entire digestive tract. Research published in 2024 and 2025 offers new insight into this mechanism – and helps explain why a taste that the food industry spent decades breeding out of our vegetables deserves a second look.

What bitter compounds are, and why they have largely disappeared from modern food

Bitter compounds are not a single chemical class but an umbrella term for structurally diverse secondary plant compounds that share one trait: a bitter taste. Chemically, they are mostly sesquiterpene lactones, iridoid glycosides, alkaloids or phenolic compounds, which primarily serve the plant as a defence against herbivores and pathogens.

Classic Central European bitter plants include:

Plant	Botanical name	Characteristic bitter compound
Artichoke	Cynara cardunculus var. scolymus	Cynarin
Dandelion	Taraxacum officinale	Taraxacin, taraxasterol
Wormwood	Artemisia absinthium	Absinthin
Centaury	Centaurium erythraea	Erythaurin, swertiamarin
Gentian	Gentiana lutea	Amarogentin
Yarrow	Achillea millefolium	Achillin, flavonoids

Over the decades, vegetables have been deliberately bred for milder, sweeter flavour profiles. Bitter compounds – and with them some aroma components – were largely lost in the process, and today's diet contains considerably less of them than the diets of earlier generations. What this might mean for the body is what current receptor research is starting to reveal.

What research has found about bitter receptors in the gut

For a long time, the accepted view was simple: bitter plants taste unpleasant, stimulate saliva flow, and that was essentially it. Modern molecular biology paints a more nuanced picture. Humans have 25 different bitter receptor subtypes, known as TAS2R receptors (Taste 2 Receptors). These are by no means limited to the mouth – they are also found in the mucosa of the stomach and intestine, in enteroendocrine cells, goblet cells and other cell types throughout the digestive tract.

A 2025 review in Critical Reviews in Food Science and Nutrition describes how intestinal TAS2R receptors are involved in regulating the release of gut hormones such as GLP-1 (glucagon-like peptide 1), thereby influencing appetite, satiety and gastric emptying. According to this review, TAS2R expression is influenced by genetics, gut microbiome composition, age and sex, and changes in an organ-specific way in obesity.

An in-vitro study from the University of Piemonte Orientale (2025, International Journal of Molecular Sciences) directly investigated for the first time how two TAS2R subtypes affect human intestinal smooth muscle cells: TAS2R38 was activated with phenylthiocarbamide, and TAS2R46 with absinthin, the main bitter compound in wormwood. Both activations triggered rapid membrane depolarisation and a rise in intracellular calcium, leading to accelerated cell contraction. The authors interpret this as the first direct evidence that these two receptor subtypes may be involved in regulating intestinal peristalsis, and propose them as potential targets for future research. This is a cell-culture study – it does not yet allow conclusions about the effect in the human body as a whole, but it provides a concrete molecular mechanism for a long-observed effect.

What research says about the traditional effect on liver and bile

The choleretic effect of bitter plants – their ability to stimulate bile production and secretion – is among the best-studied effects in phytotherapy. Bitter substances activate TAS2R receptors as soon as they contact the tongue, which triggers preparation of the digestive tract via a neural reflex; at the same time, they stimulate receptors in the stomach and duodenum involved in releasing digestive enzymes and bile acids.

For artichoke, one of the oldest controlled investigations exists: in a small, placebo-controlled, double-blind, cross-over pilot study (n = 20), a standardised artichoke extract (1.92 g) was applied directly into the duodenum. Bile flow increased by roughly 127% after 30 minutes and roughly 151% after 60 minutes compared with baseline. Given the small number of participants and the artificial route of administration, no conclusion can be drawn about the effect of an orally taken extract at usual doses – what this mainly demonstrates is the underlying choleretic mechanism.

On the hepatoprotective side, a randomised controlled clinical trial in 60 patients with non-alcoholic steatohepatitis (NASH) is available: daily intake of 2,700 mg of artichoke leaf extract over two months was associated with a significant reduction in the liver enzymes ALT and AST, as well as in cholesterol and triglycerides, compared with placebo. A later meta-analysis of several randomised controlled trials confirms an effect of artichoke preparations on ALT and AST, with stronger effects in trials lasting up to eight weeks.

Dandelion is one of Europe's most traditionally widespread liver plants. A 2025 narrative review in Pharmaceuticals (Herrera Vielma et al., University of Talca) summarises decades of – predominantly preclinical – research: animal and in-vitro studies show that dandelion extracts can protect the liver against toxin-induced damage (for example from alcohol or carbon tetrachloride), partly via modulation of oxidative stress pathways by the triterpene taraxasterol. Controlled clinical trials in humans for these hepatoprotective effects remain scarce to date; the traditional use of dandelion root for mild digestive complaints and temporary loss of appetite, however, is documented in an ESCOP monograph (European Scientific Cooperative on Phytotherapy).

What research says about the link between bitter compounds and satiety

One area currently under particularly intense investigation is satiety regulation. TAS2R receptors in enteroendocrine cells of the gut can trigger the release of GLP-1 and cholecystokinin upon contact with bitter compounds – both hormones that can enhance feelings of fullness and slow gastric emptying.

A study from KU Leuven, published in 2024 in Molecular Metabolism, examined this signalling pathway in human intestinal tissue from people with obesity, as well as in a small placebo-controlled human trial using a bitter-tasting medication (hydroxychloroquine). In gut tissue cultures, bitter substances triggered release of the satiety signal GDF15 via TAS2R receptors alongside GLP-1; in the human trial, taking the bitter medication was associated with a rise in blood GDF15 and reduced feelings of hunger. The study primarily examined bitter-tasting drugs and individual bitter compounds in the laboratory, not plant-derived bitter extracts directly – it therefore points to a possible mechanism that does not automatically transfer to herbal preparations.

Closer to the practical question is a 2021 systematic review with meta-analysis that evaluated 19 studies on the effect of non-caloric taste stimuli – including bitter compounds such as quinine – on energy intake. The finding: among the taste stimuli examined, bitter substances showed the strongest effect on eating behaviour, with reduced energy intake following administration. How strong this effect is at the concentrations found in bitter herbal preparations, and which plants trigger the strongest response, remains the subject of ongoing research.

What is known so far about bitter compounds and the gut microbiome

Another area of research concerns the interaction between bitter compounds and the gut microbiome. Studies suggest that intestinal TAS2R expression is partly shaped by microbiome composition. Conversely, many bitter plants contain inulin or other fructo-oligosaccharides that act as prebiotics and can promote the growth of certain bacterial strains. Dandelion and artichoke are among the most inulin-rich native plants; for artichoke inulin, it has also been suggested that it may influence bile salt reabsorption via the enterohepatic circulation and thereby indirectly affect lipid metabolism.

Area of application	Observed mechanism	Evidence level
Bile flow / digestion	Stimulation of bile acid production and secretion	Small placebo-controlled pilot study (artichoke, intraduodenal)
Liver enzymes in NASH	Reduction of ALT/AST with artichoke extract	RCT plus meta-analysis of several RCTs
Liver protection (dandelion)	Antioxidant activity, partly via taraxasterol	Mostly animal and in-vitro studies, 2025 narrative review
Intestinal peristalsis	TAS2R38/TAS2R46 activation by PTC/absinthin	In-vitro study on human cells (2025)
Satiety / appetite	Release of GLP-1, CCK, GDF15 via TAS2R	2021 meta-analysis and mechanistic lab studies
Gut microbiome	Prebiotic effect (inulin), TAS2R modulation	Reviews, mostly preclinical models

Safety and use: what to consider with bitter-compound preparations

Bitter herbs in customary amounts, or as standardised extracts at recommended doses, are generally considered well tolerated. However, in cases of bile duct obstruction, acute gallbladder inflammation or severe liver disease, taking choleretic bitter plants is contraindicated, since increased bile mobilisation may be undesirable in these situations. People with a known allergy to Asteraceae (daisy family) plants should be cautious with artichoke, dandelion and yarrow.

For pregnant and breastfeeding women: bitter-compound preparations at therapeutic doses should only be taken after consulting a doctor or pharmacist. Unlike some other plant extracts, no hepatotoxic effects have so far been reported for bitter compounds from artichoke or dandelion at moderate, standardised doses. Very high doses of wormwood preparations – particularly wormwood essential oil with a high thujone content – are, however, considered neurotoxic and unsuitable for prolonged use; this does not apply to standardised dry extracts at recommended doses.

Anyone taking medication metabolised by the liver, or with an existing bile duct condition, is advised to consult a doctor or pharmacist before regularly taking bitter-compound preparations.

How bitter compounds are best used

The concentration of active compounds in bitter plants varies depending on harvest time, growing region and processing. Artichoke leaves contain considerably more cynarin than the fruit itself; dandelion root harvested in autumn tends to have higher inulin and bitter-compound content than root harvested in spring.

For herbal teas, an extraction time of 5 to 10 minutes in non-boiling water (80–90°C) is considered suitable for releasing the water-soluble bitter compounds. Anyone wanting to make targeted use of the digestive stimulus traditionally takes bitter preparations before or at the start of a meal – TAS2R receptors in the gut respond to bitter-compound contact with a hormone release that typically peaks within 20 to 30 minutes.

For a standardised, everyday-friendly intake, a carefully composed herbal capsule formula that combines several traditional European bitter plants – such as artichoke, dandelion and yarrow – in defined, lab-tested standardisation is an alternative option.

Conclusion: an old flavour principle with a newly decoded mechanism

Bitter-compound research over the past few years paints a nuanced picture: what was long regarded as a simple matter of taste turns out to be a chemosensory system that extends from the tongue to the gut, linked there to digestion, liver–bile function, intestinal movement and satiety hormones. For artichoke's choleretic effect and its liver-supporting effects in clinical NASH trials, a solid evidence base exists; for the link to TAS2R-mediated satiety and for many dandelion effects, most of the evidence to date comes from cell-culture and animal studies. At the same time, breeding and processing have largely removed bitter compounds from the modern diet. Traditional European bitter plants are therefore not a relic of folk medicine but the subject of active research at varying stages of methodological maturity – with open questions remaining about dosage, individual TAS2R genetics, and long-term effects in humans.

---

This article is intended for general information about bitter-compound plants and does not replace medical advice, diagnosis or treatment. If you have health concerns, please consult a doctor or pharmacist.

---

Sources

• Camillo L, Pollastro F, Talmon M, Fresu LG: Bitter Taste Receptors 38 and 46 Regulate Intestinal Peristalsis. Int J Mol Sci. 2025 Feb 27;26(5):2092. doi: 10.3390/ijms26052092 (PMC, Open Access)
• Herrera Vielma F, Quiñones San Martin M, Muñoz-Carrasco N, Berrocal-Navarrete F, González DR, Zúñiga-Hernández J: The Role of Dandelion (Taraxacum officinale) in Liver Health and Hepatoprotective Properties. Pharmaceuticals. 2025 Jul 1;18(7):990. doi: 10.3390/ph18070990 (PMC, Open Access, narrative review)
• Liang J, Chen J, Zhao G, Wang Y: Intestinal bitter taste receptors in health: a multifactorially regulated role from the perspective of metabolic crosstalk. Critical Reviews in Food Science and Nutrition. 2025 Sep 25. doi: 10.1080/10408398.2025.2563176
• Wang Q, Farhadipour M, Thijs T, Ruilova Sosoranga E, Van der Schueren B, Ceulemans LJ, Deleus E, Lannoo M, Tack J, Depoortere I: Bitter-tasting drugs tune GDF15 and GLP-1 expression via bitter taste or motilin receptors in the intestine of patients with obesity. Mol Metab. 2024 Oct;88:102002. doi: 10.1016/j.molmet.2024.102002 (PMC, Open Access)
• Klaassen T, Keszthelyi D, Troost FJ, Bast A, Masclee AAM: Effects of gastrointestinal delivery of non-caloric tastants on energy intake: a systematic review and meta-analysis. Eur J Nutr. 2021 Sep;60(6):2923–2947. doi: 10.1007/s00394-021-02485-4 (PMC, Open Access)
• Rangboo V, Noroozi M, Zavoshy R, Rezadoost SA, Mohammadpoorasl A: The Effect of Artichoke Leaf Extract on Alanine Aminotransferase and Aspartate Aminotransferase in the Patients with Nonalcoholic Steatohepatitis. Int J Hepatol. 2016;2016:4030476. doi: 10.1155/2016/4030476 (PMC, Open Access)
• Kirchhoff R, Beckers C, Kirchhoff GM, Trinczek-Gärtner H, Petrowicz O, Reimann HJ: Increase in choleresis by means of artichoke extract. Phytomedicine. 1994;1(2):107–115. doi: 10.1016/S0944-7113(11)80027-9
• European Scientific Cooperative on Phytotherapy (ESCOP): Taraxaci radix. ESCOP Monographs, 2nd Ed. – escop.com
• Dal Cero M et al.: Trends of Medicinal Plant Use over the Last 2000 Years in Central Europe. Plants. 2023;12(1):135. doi: 10.3390/plants12010135 (PMC, Open Access)